We are developing cutting-edge cell therapies and antibody-based medicines
for the treatment of liver diseases.
people die of chronic or cirrhotic liver diseases each year in US
patients were on the waiting list for a liver transplantation in the US in 2016
liver transplants were reported in the US in 2016
At Promethera® Biosciences, we are pioneering the development of liver stem cell therapies to help patients in need of liver transplantation to restore liver health.
Our passion translates into a commitment to holistically change patients’ lives by developing liver therapies for unmet medical needs, but also by providing high quality education about liver disease and how to prevent it through healthy lifestyle choices.
We are developing groundbreaking treatments for end-stage liver disease.
HepaStem™ is our most advanced cell-based therapy and has the potential to deliver novel treatment options for chronic and acute liver diseases, especially for decompensated cirrhosis in late-stage such as Acute-on-Chronic Liver Failure (ACLF) and Non-Alcoholic SteatoHepatitis (NASH), as well as fibrosis.
At Promethera® Biosciences, we are striving to be the global leader in regenerative medicine and cell therapy for liver diseases.
Our broad intellectual property portfolio includes a proprietary antibody therapy, a human organ and cell sourcing, as well as outstanding manufacturing capabilities. It brings a unique set of technological assets, exclusive IP and know-how.